As temperatures rise across Nevada, so does the risk of overdose. This video explores the dangerous intersection of extreme heat and substance use, examining how high temperatures can intensify the effects of opioids and stimulants and increase the risk of overdose, overamping, and death.
The presentation will look at the prevalence of substance use among older people with an added focus on opioid epidemiology. It will also provide an overview for screening and identifying substance use within this population group. Additionally, a broad biopsychosocial framework and sociohistorical lens will be utilized to analyze risk factors and vulnerabilities for substance use among older people. The presentation will conclude with care considerations that integrate psychosocial aspects of well-being and reinforce the importance of psychotherapeutic interventions.
This CDC dashboard tracks fatal drug overdoses across the U.S. and by state, with data updated every month. Because overdose deaths take time to investigate and confirm, the dashboard shows two numbers: the deaths reported so far, and a predicted total that accounts for cases still under review. It also shows how overdose deaths are trending compared to the previous year and which drugs are involved, such as fentanyl, methamphetamine, and cocaine. Data are available for each state, including Nevada, and can be viewed online or downloaded.
This report examines the extent to which OTPs adopted key changes in the revised regulations and explores key barriers and facilitators to implementation.
This video explores how communities across the country are responding to the opioid epidemic with innovative, grassroots solutions. This session will highlight proven strategies for prevention, treatment access, and recovery support. Attendees will gain practical tools, hear real-world success stories, and leave them inspired to take action in their own communities.
Substance use disorders are common in the United States, with 2024 data indicating that more than 1 in 4 (25.5%) of persons 12 years of age or older used an illicit drug in the past year. The availability of highly effective direct-acting antiviral (DAA) medications has radically changed the assessment and consideration of substance use, and more specifically opioid use, in hepatitis C virus (HCV) treatment decisions. This 90-minute webinar will provide an overview of the hepatitis C virus (HCV), including a focus on defining key epidemiological aspects, contrasting recent treatment advancements, and evaluating the integration of HCV testing and treatment into medications for addiction treatment (MAT)/medications for opioid use disorder (MOUD) programs and opioid treatment programs (OTPs). Attendees will learn practical strategies to improve HCV management and enhance patient outcomes.